دورية أكاديمية
664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors.
| العنوان: | 664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors. |
|---|---|
| المؤلفون: | Kydd, A.R.1 (AUTHOR), Lee, M-J.2 (AUTHOR), Lee, S.2 (AUTHOR), Rastogi, S.2 (AUTHOR), Sato, N.2 (AUTHOR), Cordes, L.3 (AUTHOR), Ley, L.3 (AUTHOR), Sierra Ortiz, O.3 (AUTHOR), Wright, J.J.4 (AUTHOR), Streicher, H.5 (AUTHOR), Steinberg, S.6 (AUTHOR), Saraiya, B.7 (AUTHOR), Pal, S.K.8 (AUTHOR), Lara, P.N.9 (AUTHOR), Mortazavi, A.10 (AUTHOR), Costello, R.3 (AUTHOR), Niglio, S.3 (AUTHOR), Bottaro, D.11 (AUTHOR), Trepel, J.2 (AUTHOR), Apolo, A.B.12 (AUTHOR) |
| المصدر: | Annals of Oncology. 2021 Supplement 5, Vol. 32, pS690-S690. 1p. |
| مصطلحات موضوعية: | *NIVOLUMAB, *IPILIMUMAB, *IMMUNITY, *METASTASIS, *TUMORS |
| قاعدة البيانات: | Academic Search Index |
Full Text Finder | تدمد: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.08.060 |